Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shingrix Persistence of Protection
NCT04169009Phase 4Completed
- Sponsor
- University of Colorado Denver
- Start
- Jul 2020
- Primary completion
- Mar 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Zoster vaccine recombinant in herpes zoster (HZ) (4 arms), sponsored by University of Colorado Denver. Primary endpoint: Magnitude of Varicella-Zoster Virus (VZV) DNAemia at Day 7. Started Jul 2020; status: completed.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT04169009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04169009.